Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
41 Leser
Artikel bewerten:
(0)

Two Day Seminar: Lifecycle Management of Analytical Methods and Procedures According to New FDA and USP Guidelines - Opfikon, Switzerland - April 4-5, 2017 - Research and Markets

DUBLIN, Mar 06, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Lifecycle Management of Analytical Methods and Procedures - Integrate design, development, validation, and ongoing performance verification according to new FDA and USP guidelines" conference to their offering.

The 2-day workshop will give attendees the background to understand the new Analytical Procedure Lifecycle requirements and even more importantly it will focus on strategies and provide tools to implement most critical requirements. It also provides templates and examples to develop inspection ready documentation. Interactive workshop exercises will be dispersed into and between the presentations. About 50% of the total time will be dedicated to practical sessions with life examples.. After the course a variety of tools such as SOPs, validation examples and checklists will be readily available at no additional cost on a dedicated website that can be used by attendees to easily implement what they have learned in the course.

Results of analytical methods and procedures are used as the key basis to make important decision during development and manufacturing of pharmaceutical products. Therefore all regulatory agencies expect the regulated industry to have procedures and measurements in place to ensure highest reliability, accuracy and precision of such methods and procedures. The procedures should cover all lifecycle phases from design, development, validation to on-going routine use.

Managing analytical methods and procedures according to the lifecycle approach got highest attention from regulatory agencies and industry task forces. For example, the new FDA guidance Analytical Procedures and Methods Validation for Drugs and Biologics starts with suggestions for method development and includes a chapter on Lifecycle Management of Analytical Procedures. USP's Validation and Verification Expert panel just proposed a new general chapter 1220: The Analytical Procedure Lifecycle.

Attendees will:

- Learn about the regulatory background and requirements for managing the lifecycle of analytical methods and procedures
- Understand current and future industry trends: revised USP chapters 1225 and proposed chapter 1220: "The Analytical Procedure Lifecycle", and Quality by Design (QbD) principles for method development and validation
- Learn how to plan, execute and document design, development and validation of methods developed in-house
- Understand the principles of lifecycle management for compendial procedures and for managing method transfer
- Be able to explain your company's strategy for analytical procedure lifecycle
- Understand risk management strategies throughout the procedure lifecycle
- Be able to design and execute a procedure specific control strategy based on risk
- Be able to justify and document decisions about type and extend of revalidation after method changes
- Be able to define and demonstrate FDA, EU, USP and ICH compliance to auditors and inspectors
- Be able to develop inspection ready documentation during on-going routine operation
- Understanding what questions will be asked during audits and inspections and how to answer them

Who Should Attend:

- QA managers and personnel
- Quality control
- Method development
- Analytical chemists
- Validation specialists
- Laboratory managers and supervisors
- Regulatory affairs
- Training departments
- Documentation departments
- Consultants

Agenda:

The concept: 50 % of the time will be dedicated workshop type exercises using prepared fill-in templates and to interactive discussions.

Day 01 (8:30 AM - 4:30 PM)

08.30 AM - 09.00 AM: Registration

Introductions and Agenda Review

Lectures and Workshop Exercises

Lecture 1: Regulatory background and requirements

Lecture 2: Going through the new FDA Method Validation guidance - with focus on procedure lifecycle recommendations

Lecture 3: Preparing your lab for compliant validation studies

Lecture 4: The lifecycle overview on integrated design development, validation, and on ongoing performance verification

Day 02 (8:30 AM - 4:30 PM)

Lectures and Workshop Exercises

Lecture 5: The analytical target profile

Lecture 6: Procedure design and development

Lecture 7: Procedure Performance Qualification (Validation)

Lecture 8: Ongoing Performance Verification

For more information about this conference visit http://www.researchandmarkets.com/research/dmc5l6/lifecycle

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.